| pubmed-article:8093068 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8093068 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:8093068 | lifeskim:mentions | umls-concept:C0684249 | lld:lifeskim |
| pubmed-article:8093068 | lifeskim:mentions | umls-concept:C0597032 | lld:lifeskim |
| pubmed-article:8093068 | lifeskim:mentions | umls-concept:C1366557 | lld:lifeskim |
| pubmed-article:8093068 | lifeskim:mentions | umls-concept:C1704256 | lld:lifeskim |
| pubmed-article:8093068 | lifeskim:mentions | umls-concept:C0076560 | lld:lifeskim |
| pubmed-article:8093068 | lifeskim:mentions | umls-concept:C1518174 | lld:lifeskim |
| pubmed-article:8093068 | lifeskim:mentions | umls-concept:C0431085 | lld:lifeskim |
| pubmed-article:8093068 | lifeskim:mentions | umls-concept:C0887869 | lld:lifeskim |
| pubmed-article:8093068 | lifeskim:mentions | umls-concept:C0030190 | lld:lifeskim |
| pubmed-article:8093068 | lifeskim:mentions | umls-concept:C0033414 | lld:lifeskim |
| pubmed-article:8093068 | lifeskim:mentions | umls-concept:C0033268 | lld:lifeskim |
| pubmed-article:8093068 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:8093068 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:8093068 | pubmed:dateCreated | 1994-10-18 | lld:pubmed |
| pubmed-article:8093068 | pubmed:abstractText | A growing body of evidence has recently implicated TSP and TGF-beta in the process of malignancy, such as tumor cell proliferation, tumor angiogenesis, and metastasis. The purpose of the present study was to evaluate potential mechanisms of TSP and TGF-beta in tumor cell attachment and invasion. Our results indicate that both TSP and TGF-beta promoted tumor cell attachment and spreading in the presence of plasminogen. The mechanism for these effects appeared to be due, in part, to the capacity of TSP and TGF-beta to induce tumor cell production of (PAI-1). PAI-1, which is a natural inhibitor of tumor-cell associated urokinase-type plasminogen activator (uPA) activity, inhibited activation of plasminogen to plasmin in the growth media, thereby preventing plasmin-induced detachment of cells. The TSP-promoted production of PAI-1 could be inhibited not only by anti-TSP antibodies but also by a neutralizing antibody against TGF-beta. These results suggest that TSP by a mechanism involving TGF-beta can promote cell adhesion through stimulation of tumor cell secretion of PAI-1. These data provide evidence that TSP not only has the capacity of functioning as a matrix protein to directly promote cell-substratum adhesion but that TSP can also stimulate cell adhesion and spreading by modulating cell surface protease expression through stimulation of tumor-associated production of PAI-1. | lld:pubmed |
| pubmed-article:8093068 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8093068 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8093068 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8093068 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8093068 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8093068 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8093068 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8093068 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8093068 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8093068 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8093068 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8093068 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:8093068 | pubmed:issn | 0006-291X | lld:pubmed |
| pubmed-article:8093068 | pubmed:author | pubmed-author:TuszynskiG... | lld:pubmed |
| pubmed-article:8093068 | pubmed:author | pubmed-author:SolomonM PMP | lld:pubmed |
| pubmed-article:8093068 | pubmed:author | pubmed-author:AlboDD | lld:pubmed |
| pubmed-article:8093068 | pubmed:author | pubmed-author:CastiglioniAA | lld:pubmed |
| pubmed-article:8093068 | pubmed:author | pubmed-author:RothmanV LVL | lld:pubmed |
| pubmed-article:8093068 | pubmed:author | pubmed-author:GranickM SMS | lld:pubmed |
| pubmed-article:8093068 | pubmed:author | pubmed-author:ArnolettiJ... | lld:pubmed |
| pubmed-article:8093068 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8093068 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:8093068 | pubmed:volume | 203 | lld:pubmed |
| pubmed-article:8093068 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8093068 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8093068 | pubmed:pagination | 857-65 | lld:pubmed |
| pubmed-article:8093068 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:8093068 | pubmed:meshHeading | pubmed-meshheading:8093068-... | lld:pubmed |
| pubmed-article:8093068 | pubmed:meshHeading | pubmed-meshheading:8093068-... | lld:pubmed |
| pubmed-article:8093068 | pubmed:meshHeading | pubmed-meshheading:8093068-... | lld:pubmed |
| pubmed-article:8093068 | pubmed:meshHeading | pubmed-meshheading:8093068-... | lld:pubmed |
| pubmed-article:8093068 | pubmed:meshHeading | pubmed-meshheading:8093068-... | lld:pubmed |
| pubmed-article:8093068 | pubmed:meshHeading | pubmed-meshheading:8093068-... | lld:pubmed |
| pubmed-article:8093068 | pubmed:meshHeading | pubmed-meshheading:8093068-... | lld:pubmed |
| pubmed-article:8093068 | pubmed:meshHeading | pubmed-meshheading:8093068-... | lld:pubmed |
| pubmed-article:8093068 | pubmed:meshHeading | pubmed-meshheading:8093068-... | lld:pubmed |
| pubmed-article:8093068 | pubmed:meshHeading | pubmed-meshheading:8093068-... | lld:pubmed |
| pubmed-article:8093068 | pubmed:meshHeading | pubmed-meshheading:8093068-... | lld:pubmed |
| pubmed-article:8093068 | pubmed:meshHeading | pubmed-meshheading:8093068-... | lld:pubmed |
| pubmed-article:8093068 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8093068 | pubmed:articleTitle | Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro. | lld:pubmed |
| pubmed-article:8093068 | pubmed:affiliation | Medical College of Pennsylvania, Department of Surgery (Plastic), Philadelphia 19129. | lld:pubmed |
| pubmed-article:8093068 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8093068 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8093068 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8093068 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8093068 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8093068 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8093068 | lld:pubmed |
